16th Annual NATA Symposium

16th Annual NATA Symposium, Prague 2015The 16th Annual NATA Symposium on Patient Blood Management, Haemostasis and Thrombosis will take place at the Prague Congress Centre in Prague, Czech Republic, on April 16-17, 2015.

The first announcement can be downloaded in PDF or Powerpoint format. A preliminary version of the scientific programme will be released shortly.

The deadline for abstract submission is December 19, 2014. Please click on the link to download an abstract submission form

More information

Follow NATA on LinkedIn and Twitter

Join NATA's goup on LinkedIn and follow NATA on Twitter (@NATAforum) to receive the latest news on patient blood management, haemostasis and thrombosis, and to participate in discussions with colleagues in the field.
LinkedIn Group / Twitter

News from the Industry: White Paper – Red Cell Salvage: Current Status

Intraoperative Red Cell Salvage (RCS) was introduced in the early 1980s and rapidly gained clinical acceptance. Early RCS was done without cell washing, but washed RCS became the standard of care in cardiac surgery and other procedures.

RCS gained popularity because it did not carry the risk of transfusion-transmitted diseases, notably HIV and hepatitis B and C, and decreased demand for allogeneic blood. While both of these benefits are still true today, the increased safety profile of allogeneic transfusion as well as the presence of stable blood inventories have diminished their importance.

Nevertheless, strong clinical and economic reasons remain to use RCS. This white paper addresses these issues.
Read more on this

News

Antidote for rapid reversal of Pradaxa® (dabigatran etexilate) progresses into next stage of clinical investigation with study in patients

On May 22, 2014, Boehringer Ingelheim announced the next step in the clinical development of idarucizumab, an investigational antidote for rapid reversal of dabigatran-induced anticoagulation. Prior clinical research of the antidote in a healthy volunteer study with 145 participants has already demonstrated its potential for immediate, complete and sustained reversal of the anticoagulant effect of dabigatran. Idarucizumab will now be investigated in the clinical setting in patients taking Pradaxa® (dabigatran etexilate).
Read more on this

From the Literature

Sep 16, 2014

Published: Sep 2014

Frank SM, Oleyar MJ, Ness PM, Tobian AA

Reducing unnecessary preoperative blood orders and costs by implementing an updated institution-specific maximum surgical blood order schedule and a remote electronic blood release system.
Anesthesiology 2014;121:501-509.

#

NATA REVIEW:
Cost pressure in the medical sector is a strong driver for a bunch of optimisation measures that might or might...
REVIEW by:
J. Meier

Published: Sep 2014

Baron DM, Hochrieser H, Posch M, et al.

Preoperative anaemia is associated with poor clinical outcome in non-cardiac surgery patients.
Br J Anaesth 2014;113:416-423.

#

NATA REVIEW:
In a multinational prospective study with robust and transparent statistical analyses, authors from the European...
REVIEW by:
S. Kozek-Langenecker

Published: Sep 2014

Dutton RP, Lee LA, Stephens LS, Posner KL, Davies JM, Domino KB

Massive hemorrhage: a report from the Anesthesia Closed Claims Project.
Anesthesiology 2014;121:450-458.

#

NATA REVIEW:
Dutton and colleagues reviewed 3,211 closed surgical or obstetric anaesthesia malpractice claims related to haemorrhage...
REVIEW by:
P. Johansson

Published: Sep 2014

Seicean A, Alan N, Seicean S, Neuhauser D, Weil RJ

The effect of blood transfusion on short-term, perioperative outcomes in elective spine surgery.
J Clin Neurosci 2014;21:1579-1585.

#

NATA REVIEW:
The effect of perioperative blood transfusion on 30-day mortality and morbidity in elective spine surgery was...
REVIEW by:
T. Frietsch

Published: Aug 2014

N Engl J Med 2014;371:699-710.

Controlled trial of transfusions for silent cerebral infarcts in sickle cell anemia.
N Engl J Med 2014;371:699-710.

#

NATA REVIEW:
This randomised, controlled study of children (5-15 years of age) with sickle cell anaemia studied the value...
REVIEW by:
L. T. Goodnough

Published: Jul 2014

Piccini JP, Garg J, Patel MR, et al.

Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial.
Eur Heart J 2014;35:1873-1880.

#

NATA REVIEW:
Rivaroxaban is a novel oral anticoagulant directed against factor Xa. In clinical trials, rivaroxaban was...
REVIEW by:
M. Levi